Suppr超能文献

70岁以下接受经导管主动脉瓣植入术的患者:手术结果和中期生存率。

Patients younger than 70 undergoing transcatheter aortic valve implantation: Procedural outcomes and mid-term survival.

作者信息

Ancona Marco B, Toscano Evelina, Moroni Francesco, Ferri Luca A, Russo Filippo, Bellini Barbara, Sorropago Antonio, Mula Caterina, Festorazzi Costanza, Gamardella Marco, Vella Ciro, Beneduce Alessandro, Romano Vittorio, Belluschi Igor, Buzzatti Nicola, Agricola Eustachio, Montorfano Matteo

机构信息

Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Interventional Cardiology Department, Policlinico di Monza, Monza, Italy.

出版信息

Int J Cardiol Heart Vasc. 2021 Jun 9;34:100817. doi: 10.1016/j.ijcha.2021.100817. eCollection 2021 Jun.

Abstract

INTRODUCTION

Based on recent data, the indication for transcatheter aortic valve implantation (TAVI) is expanding to individuals at lower surgical risk, who are generally younger than subjects historically treated for severe aortic stenosis. Indeed, younger patients have traditionally been under-represented in current TAVI literature. The aim of the present study is to report about clinical features, procedural outcomes and mid-term outcomes of patients younger than 70 who underwent TAVI in a single high-volume center.

MATERIALS AND METHODS

Consecutive patients younger than 70 years of age who underwent TAVI for severe, symptomatic aortic stenosis between 2007 and 2019 at a single, tertiary referral center have been included in this retrospective study. Procedural and mid-term outcomes were analyzed, comparing 1st generation with 2nd generation devices.

RESULTS

Between 2007 and 2019, 1740 TAVI procedures were performed in our center. Among these, one hundred twenty-nine (7.4%) patients were younger than 70 years at the time of the intervention and were included in the present analysis. Fifty-eight patients (45%) were implanted with a 1st generation prosthesis while seventy-one patients (55%) were implanted with a 2nd generation device. Reasons which lead to a transcatheter approach in this population were: previous CABG (27.9%); porcelain aorta (24%); severe left ventricular systolic dysfunction (21.7%); prior chest radiation (19.4%); severe lung disease (8.5%); hemodynamic instability (7.0%); advanced liver disease (4.6%) and active cancer (3.9%). Overall device success rate was 89%, with no differences among 1st and 2nd generation devices. Threeyears all-cause mortality was 34%, with no difference among the two groups. Low incidence of aortic-valve re-intervention was observed at mid-term follow-up (late valve re-intervention = 2.3%).

CONCLUSIONS

TAVI in young patient with appropriate indication for intervention is a safe procedure, associated with low rate of in hospital mortality and low rate of severe complications both with 1st and with 2nd generation devices. When considering long term durability, more data are needed; in our case series long-term follow up shows a good survival and also an extremely low rate of valve re-intervention.

摘要

引言

基于近期数据,经导管主动脉瓣植入术(TAVI)的适应证正在扩大至手术风险较低的个体,这些个体通常比历史上接受严重主动脉瓣狭窄治疗的患者更年轻。事实上,年轻患者在当前TAVI文献中的代表性一直不足。本研究的目的是报告在一个高容量中心接受TAVI的70岁以下患者的临床特征、手术结果和中期结果。

材料与方法

本回顾性研究纳入了2007年至2019年期间在一家三级转诊中心因严重、有症状的主动脉瓣狭窄接受TAVI的连续70岁以下患者。分析了手术和中期结果,比较了第一代和第二代装置。

结果

2007年至2019年期间,我们中心共进行了1740例TAVI手术。其中,129例(7.4%)患者在干预时年龄小于70岁,纳入本分析。58例(45%)患者植入了第一代假体,71例(55%)患者植入了第二代装置。导致该人群采用经导管方法的原因有:既往冠状动脉旁路移植术(CABG)(27.9%);瓷化主动脉(24%);严重左心室收缩功能障碍(21.7%);既往胸部放疗(19.4%);严重肺部疾病(8.5%);血流动力学不稳定(7.0%);晚期肝病(4.6%)和活动性癌症(3.9%)。总体装置成功率为89%,第一代和第二代装置之间无差异。三年全因死亡率为34%,两组之间无差异。中期随访观察到主动脉瓣再次干预的发生率较低(晚期瓣膜再次干预=2.3%)。

结论

对于有适当干预适应证的年轻患者,TAVI是一种安全的手术,第一代和第二代装置的住院死亡率和严重并发症发生率均较低。在考虑长期耐久性时,需要更多数据;在我们的病例系列中,长期随访显示生存率良好,瓣膜再次干预率极低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b9/8207181/f0ad69940a8f/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验